Rilzabrutinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Rilzabrutinib. Educational only — not medical advice.
Labeled uses
WAYRILZ is indicated for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Source: FDA labeling via NIH DailyMed (set 95ffd367…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.